Millipore Sigma Vibrant Logo

533982 Dock5 Inhibitor, C21 - CAS 54129-15-6 - Calbiochem

533982
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₁₂H₉Cl₂NO₂S 54129-15-6

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
5.33982.0001
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 50 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA cell-permeable, bioavailable, non-toxic benzenesulfonamide compound that directly blocks Dock5-mediated Rac activation (kcat/KM = 7.9 x 104 & 9.5 x 104 M-1s-1 for Rac1 & Rac2 by Dock5-DHR2, respectively) with selectivity over RhoA and Cdc42. At higher concentrations, affects Dock1 and Dock2 guanine nucleotide exchange factor activity. Shown to reversibly perturb podosome organization and inhibit osteoclastic bone degradation in a dose-dependent manner. Efficiently prevents both arthritis and metastasis-induced bone loss while preserving bone formation in several osteolytic disease mouse model (25 mg/kg, i.p. or i.v., 5 days a week for 4 weeks). Unlike alendronate (Cat. No. 126855), C21 does not impair bone formation.

      Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
      Catalogue Number533982
      Brand Family Calbiochem®
      SynonymsN-(3,5-Dichlorophenyl)benzenesulfonamide
      References
      ReferencesVives, V., et al. 2015. Nat. Commun. 6, 6218.
      Vives, V., et al. 2011. J. Bone Miner. Res. 26, 1099.
      Product Information
      CAS number54129-15-6
      FormGrey powder
      Hill FormulaC₁₂H₉Cl₂NO₂S
      Chemical formulaC₁₂H₉Cl₂NO₂S
      ReversibleY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetDock5
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Dock5 Inhibitor, C21 - CAS 54129-15-6 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      References

      Reference overview
      Vives, V., et al. 2015. Nat. Commun. 6, 6218.
      Vives, V., et al. 2011. J. Bone Miner. Res. 26, 1099.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision14-July-2017 JSW
      SynonymsN-(3,5-Dichlorophenyl)benzenesulfonamide
      DescriptionA cell-permeable, bioavailable, non-toxic benzenesulfonamide compound that directly blocks Dock5-mediated Rac activation (kcat/KM = 7.9 x 104 & 9.5 x 104 M-1s-1 for Rac1 & Rac2 by Dock5-DHR2, respectively) with selectivity over RhoA and Cdc42. At higher concentrations, affects Dock1 and Dock2 guanine nucleotide exchange factor activity. Shown to reversibly perturb podosome organization and inhibit osteoclastic bone degradation in a dose-dependent manner. Efficiently prevents both arthritis and metastasis-induced bone loss while preserving bone formation in several osteolytic disease mouse model (25 mg/kg, i.p. or i.v., 5 days a week for 4 weeks). Unlike alendronate (Cat. No. 126855), C21 does not impair bone formation.
      FormGrey powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number54129-15-6
      Chemical formulaC₁₂H₉Cl₂NO₂S
      Purity≥98% by HPLC
      SolubilityDMSO (50 mg/ml)
      Storage +2°C to +8°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesVives, V., et al. 2015. Nat. Commun. 6, 6218.
      Vives, V., et al. 2011. J. Bone Miner. Res. 26, 1099.